Physician profile
Trisha C Beute
NPI 1518938547
$2,427.46
in general payments reported to CMS, 2019-2025
24 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $130 · 2021: $104 · 2022: $290 · 2023: $599 · 2024: $689 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.81 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $479.53 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $390.83 | 2023-2025 | Otezla, Enbrel, Otezla |
| Sun Pharmaceutical Industries INC. | $297.98 | 2019-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $243.82 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $203.34 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $143.59 | 2019-2025 | |
| Almirall LLC | $104.01 | 2021 | |
| Pfizer INC. | $78.56 | 2019-2023 | |
| Arcutis Biotherapeutics, INC. | $59.97 | 2023-2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.61 | 2023-2024 | Spevigo |
| Strata Skin Sciences, INC. | $48.80 | 2019-2024 | Xtrac |
| Ucb, INC. | $44.10 | 2019-2022 | |
| Genentech USA, INC. | $38.10 | 2019-2020 | |
| Celgene Corporation | $33.22 | 2019 | |
| Leo Pharma INC. | $31.97 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $28.98 | 2022-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Galderma Laboratories, L.P. | $28.87 | 2019-2023 | Aklief |
| Incyte Corporation | $23.49 | 2025 | Opzelura |
| Genzyme Corporation | $20.17 | 2022 | |
| Dermira, INC. | $18.05 | 2019 | |
| Lilly USA, LLC | $17.83 | 2019 | |
| Dusa Pharmaceuticals, INC. | $14.91 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.98 | 2025 | Jublia, Siliq, Cabtreo |
| Merck Sharp & Dohme LLC | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Beute listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.